HolleyPharm To Inject RMB 50 Million Into Holley-Cotec
This article was originally published in PharmAsia News
Executive Summary
To further consolidate its artemisinin-related business, HolleyPharm will pump in RMB 50 million into its Beijing subsidiary Beijing Holley-Cotec Pharmaceuticals. With the capital injection, the latter's registered capital will be increased from the current RMB 5 million to RMB 50 million in the initial stage, and eventually to RMB 100 million. In addition, HolleyPharm will gradually transfer its stakes in artemisinin-related firms including Holley Wuling Mountain, Holley (Jishou), Holley Nanhu and Beibei pharmaceutical base to Holly-Cotec. The reorganization aims to establish an artemisinin-centered business platform with higher efficiency, better economic performance and greater competitiveness. (Click here for more - Chinese Language)